Latest Going Concern News

PainChek Limited reported a 24% revenue increase to $4.8 million for FY25, narrowing its net loss by 7%, while progressing toward FDA clearance for its Adult PainChek App in the US and launching its Infant App in Australia.

Scalare Partners Holdings Limited reported a 26% increase in total revenues to $3.54 million for FY25, driven by strong growth in founder support services and strategic acquisitions. However, the Group recorded a statutory loss of $2.65 million amid increased structural and compliance costs following its ASX listing and expansion.

TrivarX Limited reported a reduced net loss of $943K for FY25 alongside a $3.68 million equity raise, yet flagged material uncertainty over its ability to continue as a going concern.

Hiremii Limited reported a near-flat revenue for FY2025 with a 25% increase in net loss, while pushing forward its AI-driven recruitment platform and completing a key acquisition to expand market reach.

Control Bionics Limited reported a 14.8% revenue increase to $6.14 million for FY2025 but also a 3.3% rise in net loss to $6.11 million, while pursuing a $2 million rights issue and expanding its investment portfolio.

RemSense Technologies posted a 107% revenue surge to $3.44 million in FY2025 alongside a 67% reduction in net loss, driven by operational efficiencies and strong client demand. The company achieved positive cash EBITDA and strengthened its global footprint with Tier 1 clients.

WhiteHawk Limited reports an 8.6% revenue increase and a 26% reduction in net loss for H1 2025, alongside new US government contracts and a $1.56 million capital raise.

Rent.com.au Limited reported a $3.69 million net loss for FY25 amid modest revenue growth, while securing significant funding to scale its RentBond® product and reshaping its leadership team.

BDO Audit has completed its review of HeraMED Limited’s half-year financial report for June 2025, confirming compliance with accounting standards but highlighting significant uncertainty over the company’s ability to continue as a going concern.

Cynata Therapeutics reported a $9.39 million net loss for FY2025, slightly improved from the prior year, while progressing multiple clinical trials with key results expected in 2026. The company maintains a solid cash position and funding runway through mid-2026, supported by recent capital raises and an equity subscription agreement.

Sparc Technologies reported a narrower FY25 loss alongside progress in green hydrogen and graphene additive projects, supported by government grants and a successful capital raise.

ARC Funds Limited posted a $2.45 million loss for FY2025, driven by strategic investments and increased transaction costs as it expands its funds management platform.